Rheumatoid Arthritis with MTX Contraindication and Poor Prognostic Factors — When Initial csDMARD Therapy Has Not Reached Target

This protocol addresses the next treatment step in rheumatoid arthritis patients who cannot use methotrexate and who carry poor prognostic factors — when the first csDMARD-based strategy has failed to achieve the treatment target.

Clinical situation

The patient has a contraindication or early intolerance to methotrexate, with one or more of the following poor prognostic factors present:

Elevated rheumatoid factor (RF) and/or ACPA, particularly at high levels
High swollen joint count
High acute phase reactant levels
Presence of early erosions
Failure of two or more csDMARDs
Persistently moderate or high disease activity despite csDMARD therapy

Previous therapy — treatment target not met

The initial csDMARD strategy — leflunomide or sulfasalazine combined with short-term glucocorticoids — did not achieve the required treatment targets:

At least 50% improvement in disease activity within 3 months; sustained remission or low disease activity by 6 months.

This protocol defines the structured next step when those goals remain unmet.

Next-line approach (partial overview)

When poor prognostic factors are present and the first csDMARD strategy has not reached target, adding a biologic DMARD (bDMARD) in combination with the continuing csDMARD is the principal consideration — or alternatively, a JAK inhibitor following assessment of relevant risk factors. Special combination considerations apply for patients who cannot use a csDMARD as comedication.

Full agent selection, combination guidance, and risk-stratification criteria are available in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/ard-2022-223356

In patients with a contraindication to MTX (or early intolerance), leflunomide or sulfasalazine should be considered as part of the (first) treatment strategy.
If the treatment target is not achieved with the first csDMARD strategy, when poor prognostic factors are present, a bDMARD should be added; JAK-inhibitors may be considered, but pertinent risk factors must be taken into account.
Presence of RF and/or ACPA, especially at high levels.
Presence of early erosions.
Failure of 2 or more csDMARDs.
bDMARDs and tsDMARDs should be combined with a csDMARD; in patients who cannot use csDMARDs as comedication, IL-6 pathway inhibitors and tsDMARDs may have some advantages compared with other bDMARDs.
Treatment should be aimed at reaching a target of sustained remission or low disease activity in every patient.
Monitoring should be frequent in active disease (every 1–3 months); if there is no improvement by at most 3 months after the start of treatment or the target has not been reached by 6 months, therapy should be adjusted.

View source ↗